Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases-Reference-Cited by-同舟云学术

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

Published:2013-09-04 Issue:7 Volume:191 Page:3568-3577
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Van Rompaey Luc,Galien René,van der Aar Ellen M.,Clement-Lacroix Philippe,Nelles Luc,Smets Bart,Lepescheux Liên,Christophe Thierry,Conrath Katja,Vandeghinste Nick,Vayssiere Béatrice,De Vos Steve,Fletcher Stephen,Brys Reginald,van ’t Klooster Gerben,Feyen Jean H. M.,Menet Christel

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference38 articles.

1. Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease

2. JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies

3. Janus kinases in immune cell signaling

4. A new modality for immunosuppression: targeting the JAK/STAT pathway

5. JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

Cited by 194 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

2. Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors;Bioorganic Chemistry;2024-08

3. Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma;Nature Communications;2024-06-21

4. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma;Science;2024-06-21

5. Janus Kinases and Autoimmunity: Bridging Pathways to Therapy;International Journal of Drug Discovery and Pharmacology;2024-06-05